Overview

The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.

Eligibility

Inclusion Criteria:

        Adult and pediatric patients with hematological malignancies in complete remission (CR),
        partial remission (PR) or with stable disease
          -  Acute myeloid leukemia (AML):
               -  Patients with high-risk AML in first complete remission (CR1)
               -  Patients with relapsed or primary therapy-refractory AML
          -  Acute lymphoid leukemia (ALL):
               -  Patients with high-risk ALL in CR1
               -  Patients with relapsed or primary refractory ALL
          -  Hodgkin's disease: Patients with relapsed or primary refractory Hodgkin's disease
          -  Non-Hodgkin's lymphoma: Patients with relapsed or primary refractory Non- Hodgkin's
             lymphoma
          -  Myelodysplastic Syndrome (MDS)/ Myeloproliferative Syndrome (MPS):
             °Patients with refractory MDS/MPS
          -  Multiple myeloma (MM): Patients with relapsed or refractory multiple myeloma
        Exclusion Criteria:
          -  Age >65 years or <8 weeks
          -  Patients with progressive disease prior hematopoietic cell transplantation (HCT)
          -  <3 months after preceding HCT
          -  Treatment with T-cell or Interleukin-2 (IL-2) targeted medication (e.g. alemtuzumab,
             basiliximab) within 60 days prior to study product infusion
          -  Treatment with prednisolone at >2 mg/kg/day (or equivalent dosing of alternative
             glucocorticosteroids) at time of study product infusion.
          -  Known allergy/hypersensitivity to any component of the study product
          -  Treatment with another investigational drug within one month before inclusion
          -  History of neurological impairment (active seizures, severe peripheral neuropathy,
             signs of leukoencephalopathy, active Central Nervous System (CNS) infection) Note: For
             patients with heavy pretreatment with irradiation or intrathecal chemotherapy
             pre-transplant CNS MRI and neurological consultation are mandatory.
          -  Fungal infections with radiological and clinical progression
          -  Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases
             higher than 400 U/L
          -  Chronic active viral hepatitis
          -  Ejection fraction <40% or Shortening fraction <20% on echocardiography. Patients with
             > grade II hypertension by Common Toxicity Criteria (CTC)
          -  Creatinine clearance below threshold defined for stem cell transplantation according
             to local clinical standard
          -  Respiratory failure necessitating supplemental oxygen
          -  HIV infection
          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential not willing to use an effective method of birth control during study
             treatment and for at least 12 months thereafter Note: Women of childbearing potential
             must have a negative serum pregnancy test at study entry.
          -  Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes,
             congestive heart failure, myocardial infarction within 6 months prior to the study,
             unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled
             infection) which by assessment of the treating physician could compromise
             participation in the study
          -  Patients with a history of psychiatric illness or a condition which could interfere
             with their ability to understand the requirements of the study (this includes
             alcoholism/drug addiction)
          -  Patients unwilling or unable to comply with the protocol or unable to give informed
             consent